Ivaylo Gentschev, PD Dr.
PD Dr. Ivaylo Gentschev
Group: Molecular Oncology
Phone: +49 931 - 31-89187
E-mail: ivaylo.gentschev@uni-wuerzburg.de
Room: B118
Curriculum vitae
Name | PD Dr. Ivaylo Gentschev |
|
Position | Project leader | |
Affiliation
| Chair of Biochemistry/CTRC, Theodor-Boveri-Institute at the Biocentre | |
|
Career | 1999 - present | Private lecturer (PD), Faculty memeber, Faculty of Biology, University of Würzburg, Germany | |
| 2018 - present | Project leader, Cancer Therapy Research Center (CTRC), University of Würzburg, Germany | |
| 2017 - 2018 | Senior Research fellow - StemImmune Corporation (now Calidi Biotherapeutics), San Diego, USA | |
| 2007 - present | Principal Investigator, Graduate School of Life Science, University of Würzburg, Germany | |
| 2007 - 2015 | Director of veterinary vaccine design and veterinary tumor detection and therapy, Genelux Corporation, San Diego USA | ||
| 2002 - 2007 | Senior research fellow and group leader at Institute of Medical Radiation an Cel Research (MRCRI, University of Würzburg, Germany | |
| 1996 - 2002 | Assistant professor and group leader, Dept. of Microbiology, University of Würzburg, Germany | |
| 1991 - 1999 | Venia legendi (Habilitation) Microbiology, University of Würzburg, Germany | ||
| 1991 - 1996 | Post-Doc, Dept. of Microbiology, University of Würzburg, Germany | ||
| 1987 - 1991 | Ph.D. Microbiology, Dept. of Microbiology, University of Würzburg, Germany | ||
| 1986 - 1987 | Research Scientist, Academy of Sciences Sofia, Bulgaria | ||
| 1985 | M.S. Biochemistry, Martin-Luther-University, Halle/Salle, Germany | ||
Research Fields | Development of anti-cancer vaccines and therapeutics on the basis of viruses and bacteria. Protein and DNA delivery systems for development of subunit vaccines |
Selected Awards | Since 2012: Editorial Board of Bioengineered 2010 - 2019 Editorial Board of Advances in Preventive Medicine 2009 - 2011 Editorial Board of Bioengineered Bugs 2010 Selection for appointment of volunteer faculty member at UCSD Radiation Oncology, San Diego, USA 1999 Max-von-Pettenkofer Award for vaccine development |
Publications
Selected Publications
Full record: >100 publications: 80 original papers, 19 reviews, 14 published meeting abstracts, 8 book chapters, 4 patents; Google Scholar (h index = 37), For a complete list of publications please click (https://www.google.com/search (ivaylo gentschev google scholar)
Key publications:
Tumor colonization and tumor therapy with an intranasally-applied Escherichia coli Nissle 1917 strain is strongly affected by the gut microbiome in tumor-bearing mice. I.Gentschev, M.Ye, I. Petrov, A.Cecil, T. Oelschaeger, AA. Szalay. Cancers submitted
Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a “Trojan Horse” in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas. I Petrov, I Gentschev*, A Vyalkova, MI Elashry, MC Klymiuk, S Arnhold, AA Szalay. Viruses 12 (7), 750 (2020)
Oncolytic virotherapy of canine and feline cancer. I Gentschev, SS Patil, I Petrov, J Cappello, M Adelfinger, AA Szalay. Viruses 6 (5), 2122-2137
Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof. IN Gentschev, J Fensterle, UR Rapp, W Goebel.US Patent 8,669,091 (2014)
Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma.I Gentschev, M Adelfinger, R Josupeit, S Rudolph, K Ehrig, U Donat, AA Szalay. PloS one 7 (5), e37239 (2012)
Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B.J Fensterle, B Bergmann, C Yone, C Hotz, SR Meyer, S Spreng, W Goebel, UR Rapp, I Gentschev. Cancer gene therapy 15 (2), 85-93 (2008)
Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. AY Yong, S Shabahang, TM Timiryasova, Q Zhang, R Beltz, I Gentschev, AA Szalay. Nature biotechnology 22 (3), 313-320 (2004) The E. coli α-hemolysin secretion system and its use in vaccine development.I Gentschev, G Dietrich, W Goebel. Trends in microbiology 10 (1), 39-45(2002) The Escherichia coli haemolysin secretion apparatus: a potential universal antigen delivery system in Gram‐negative bacterial vaccine carriers. S Spreng, G Dietrich, W Goebel, I Gentschev. Molecular microbiology 31 (5), 1596-1598 (1999) Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide L. monocytogenes. G Dietrich, A Bubert, I Gentschev, Z Sokolovic, A Simm, A Catic, Nature biotechnology 16 (2), 181-185(1998) Development of antigen-delivery systems, based on the Escherichia coli hemolysin secretion pathway. I Gentschev, H Mollenkopf, Z Sokolovic, J Hess, SHE Kaufmann, W Goebel. Gene 179 (1), 133-140 (1996) Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Hess J, Gentschev I, Miko D, Welzel M, Ladel C, Goebel W, Kaufmann SH. Proc Natl Acad Sci U S A. 93(4):1458-63 (1996) Topological and functional studies on HlyB of Escherichia coli . I Gentschev, W Goebel. Molecular and General Genetics MGG 232 (1), 40-48 (1992) |
